CA2989341C - Method for treating or preventing dry eyes - Google Patents

Method for treating or preventing dry eyes Download PDF

Info

Publication number
CA2989341C
CA2989341C CA2989341A CA2989341A CA2989341C CA 2989341 C CA2989341 C CA 2989341C CA 2989341 A CA2989341 A CA 2989341A CA 2989341 A CA2989341 A CA 2989341A CA 2989341 C CA2989341 C CA 2989341C
Authority
CA
Canada
Prior art keywords
compound
formula
treating
tetrahydroxystilbene
dry eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2989341A
Other languages
English (en)
French (fr)
Other versions
CA2989341A1 (en
Inventor
Rong-Tsun Wu
Lin-Yea HORNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2989341A1 publication Critical patent/CA2989341A1/en
Application granted granted Critical
Publication of CA2989341C publication Critical patent/CA2989341C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2989341A 2015-06-16 2016-06-16 Method for treating or preventing dry eyes Active CA2989341C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180450P 2015-06-16 2015-06-16
US62/180,450 2015-06-16
PCT/CN2016/000309 WO2016201953A1 (en) 2015-06-16 2016-06-16 Method for treating or preventing dry eyes

Publications (2)

Publication Number Publication Date
CA2989341A1 CA2989341A1 (en) 2016-12-22
CA2989341C true CA2989341C (en) 2021-12-07

Family

ID=57544797

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989341A Active CA2989341C (en) 2015-06-16 2016-06-16 Method for treating or preventing dry eyes

Country Status (9)

Country Link
US (1) US10383885B2 (https=)
EP (1) EP3310361B1 (https=)
JP (1) JP6960399B2 (https=)
KR (1) KR102606948B1 (https=)
CN (1) CN107921053B (https=)
AU (1) AU2016279139B2 (https=)
CA (1) CA2989341C (https=)
TW (1) TWI649083B (https=)
WO (1) WO2016201953A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1332726A (zh) * 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
NZ517556A (en) * 1999-09-06 2003-08-29 Ono Pharmaceutical Co N-[o-(p-pivaloyloxybenzenesulphonyl-amino)benzoyl]glycine as preventive and therapeutic agents for eye diseases
CN1257176C (zh) * 2003-10-24 2006-05-24 广州中医药大学热带医学研究所 2，3，5，4＇－四羟基二苯乙烯－2－O－β－D－葡萄糖苷在制备降血脂药物中的应用
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20100160243A1 (en) * 2008-12-24 2010-06-24 National Yang-Ming University Compounds and methods for enhancing erythropoiesis
CN101966193B (zh) * 2010-10-29 2012-05-23 西南交通大学 2,3,5,4’-四羟基二苯乙烯-2-O-β-D-葡萄糖苷在制备治疗抑郁症药物中的应用
US20120164242A1 (en) * 2010-12-27 2012-06-28 Wen-Jen Yu Novel methods for modulating melanin production
AU2013384234A1 (en) * 2013-03-28 2015-10-15 Rong-Tsun Wu Composition and method for inducing EPO-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell
CN103524576A (zh) * 2013-08-12 2014-01-22 天津中医药大学 2,3,5,4′-四羟基二苯乙烯-2-O-β-D-葡萄糖苷的分离纯化工艺

Also Published As

Publication number Publication date
KR20180019151A (ko) 2018-02-23
AU2016279139B2 (en) 2020-09-10
EP3310361A1 (en) 2018-04-25
JP6960399B2 (ja) 2021-11-05
TW201717965A (zh) 2017-06-01
AU2016279139A1 (en) 2018-01-04
EP3310361A4 (en) 2019-01-23
WO2016201953A1 (en) 2016-12-22
TWI649083B (zh) 2019-02-01
CN107921053A (zh) 2018-04-17
US10383885B2 (en) 2019-08-20
JP2018517776A (ja) 2018-07-05
US20180193369A1 (en) 2018-07-12
CA2989341A1 (en) 2016-12-22
KR102606948B1 (ko) 2023-11-27
CN107921053B (zh) 2020-09-01
EP3310361B1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
Dang et al. Treatment of non-infectious corneal injury: review of diagnostic agents, therapeutic medications, and future targets
Cheng et al. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Cholkar et al. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045)
US10010586B2 (en) Method of treating intraocular tissue pathologies with nerve growth factor
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
Han et al. Antiangiogenic effects of catalpol on rat corneal neovascularization
Liu et al. Bone marrow mesenchymal stem cells enhance autophagy and help protect cells under hypoxic and retinal detachment conditions
Mancini et al. Topical insulin used alone or in combination with drug-depository contact lens for refractory cases of neurotrophic keratopathy
EP3968949A1 (en) Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations for prevention of macular thickening and its associated visual outcomes after lens surgery
US12510536B2 (en) Method for changing condition of eyelid of hairless animal
CA2989341C (en) Method for treating or preventing dry eyes
Salazar-Quiñones et al. Management of corneal neurotrophic ulcers with Cacicol®-RGTA (ReGeneraTing Agent): A case series
US11426346B2 (en) Lutein-containing ophthalmic composition
US20210228622A1 (en) Compositions of oxyhydrogen and the thereapeutic use thereof for ocular conditions
US20250360185A1 (en) Compositions comprising pedf-derived short peptides for the treatment of dry eye diseases
Isleyen et al. Effects of Dexpanthenol on Corneal Neovascularization and Inflammation on Rat Model
RU2710553C1 (ru) Способ лечения пациентов после факоэмульсификации возрастной катаракты
RU2694226C1 (ru) Фармацевтическая композиция для лечения заболеваний глаз, сопровождающихся окислительным стрессом, и способ ее применения
Al-Saedi Formulation and in vitro evaluation of cyclosporine A inserts prepared using HPMC for treating dry eye disease
WO2023183603A1 (en) Topical use of terbinafine and similar compounds for inflammatory ocular conditions
Koçluk et al. Ceratoconjuntivite atópica: resultados a longo prazo do tratamento clínico e da ceratoplastia penetrante
PL237591B1 (pl) Nowe zastosowanie medyczne kwasu kynureninowego i jego soli w leczeniu spojówki i rogówki oka

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190801

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - SMALL

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250501

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250501

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - SMALL

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251030

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251105